Hosted on MSN17d
Roche’s STI assay panels gain FDA 510(k) clearance and CLIA waiver
Roche has received 510(k ... Designed for ease of use in near-patient settings, the cobas liat assays require minimal training, ensuring rapidness for healthcare professionals.
manilatimes20d
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15-49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to ...
PharmiWeb19d
Roche receives FDA clearance with CLIA waiver for…
Basel, 22 January 2025 - Roche (SIX: RO, ROG; OTCQX ... reliability and minimal training. The cobas liat system is a closed system, reducing contamination risks and enhancing the reliability of ...
labmate-online.com11d
Roche receives FDA clearance, CLIA waiver, for cobas® liat tests to provide point of care diagnosis of STIs
Tests broaden access to accurate, easy-to-use diagnostics for patients in a decentralised setting Roche has been granted US ...
Mena FN20d
Roche Receives FDA Clearance With CLIA Waiver For Cobas® Liat Molecular Tests To Diagnose Sexually Transmitted Infections At The Point Of Care
Basel, 22 January 2025 - Roche (SIX: RO, ROG ... reliability and minimal training. The cobas liat system is a closed system, reducing contamination risks and enhancing the reliability of results.
Yahoo Finance18d
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
Basel, 22 January 2025 - Roche (SIX: RO, ROG ... waiver for its cobas® liat sexually transmitted infection (STI) multiplex assay panels. These panels, including tests for chlamydia and gonorrhea ...